• COVID-19
  • Allergies and Infant Formula
  • Pharmacology
  • Telemedicine
  • Drug Pipeline News
  • Influenza
  • Allergy, Immunology, and ENT
  • Autism
  • Cardiology
  • Emergency Medicine
  • Endocrinology
  • Adolescent Medicine
  • Gastroenterology
  • Infectious disease
  • Nutrition
  • Neurology
  • Obstetrics-Gynecology & Women's Health
  • Developmental/Behavioral Disorders
  • Practice Improvement
  • Gynecology
  • Respiratory
  • Dermatology
  • Diabetes
  • Mental Health
  • Oncology
  • Psychiatry
  • Animal Allergies
  • Alcohol Abuse
  • Rheumatoid Arthritis
  • Sexual Health
  • Pain

Answer to Last Month’s Online Challenge

Article

Infantile seborrhea has many of the features of the other papulosquamous conditions listed, but the diagnosis is most commonly clinically evident on examination alone. If you are unsure, a KOH preparation will quickly sort out the dermatophytes. Also, the lack of itch makes atopic dermatitis very unlikely.

Figure

DISCUSSION: Option C, Seborrhea, is the correct answer.

Infantile seborrhea has many of the features of the other papulosquamous conditions listed, but the diagnosis is most commonly clinically evident on examination alone. If you are unsure, a KOH preparation will quickly sort out the dermatophytes. Also, the lack of itch makes atopic dermatitis very unlikely.

The difficulty arises in excluding psoriasis. Many consultants consider that there is significant overlap between seborrhea and psoriasis because many children with seborrhea also have features of psoriasis. I like to reserve my final thoughts; I am not comfortable excluding psoriasis until I have seen a rapid response to therapy, and until I see that this response continues if the condition recurs.

Pityrosporum ovale-yeast commonly found as part of the skin's normal microflora-is the most likely cause of this condition. There are a number of immunologic and biochemical theories to explain individual susceptibility or causation but, for the clinician, the often rapid and complete response to topical azoles is strong evidence that this organism plays a significant role in the etiology.

Related Videos
Lawrence Eichenfield, MD
Lawrence Eichenfield, MD | Image credit: KOL provided
FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.
Related Content
© 2024 MJH Life Sciences

All rights reserved.